Non-Small Cell Lung Cancer (NSCLC)-Clinical Trial Insight
- September 2020
- 200 pages
Non-Small Cell Lung Cancer Understanding
Non-Small Cell Lung Cancer (NSCLC): Overview
Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) are often similar.
The three main histological subtypes of Non-Small Cell Lung Cancer are:
Adenocarcinoma: About 40% of all lung cancers are adenocarcinomas. These tumours start in mucus-producing cells that line the airways.
Squamous cell carcinoma (SCC): About 25-30% of all lung cancers are Squamous cell carcinoma. This type of cancer develops in cells that line the airways and is usually caused by smoking.
Large cell (undifferentiated) carcinoma: This type makes up around 10-15% of all lung cancers. It gets its name from the way that the cancer cells look when they are examined under a microscope.
Symptoms of lung cancer that are in the chest:
Coughing, especially if it persists or becomes intense
Pain in the chest, shoulder, or back unrelated to pain from coughing
A change in color or volume of sputum
Shortness of breath
Changes in the voice or being hoarse
Harsh sounds with each breath (stridor)
Recurrent lung problems, such as bronchitis or pneumonia
Coughing up phlegm or mucus, especially if it is tinged with blood
Coughing up blood
Tests that examine the lungs are used to diagnose and stage non-small cell lung cancer.
Physical exam and health history: An exam of the body to check general signs of health, including checking for signs of disease, such as lumps or anything else that seems unusual.
Laboratory tests: Medical procedures that test samples of tissue, blood, urine, or other substances in the body. These tests help to diagnose disease, plan and check treatment, or monitor the disease over time.
Treatment primarily involves surgery, chemotherapy, or radiation therapy. Because most lung cancers cannot be cured with currently available therapeutic modalities, the appropriate application of skilled palliative care is an important part of the treatment of patients with Non-Small Cell Lung Cancer.
Non-Small Cell Lung Cancer Emerging Drugs Chapters
This segment of the Non-Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Non-Small Cell Lung Cancer Emerging Drugs
Canakinumab is an interleukin (IL)-1 blocker that is being evaluated in CANOPY trial. CANOPY-A is a Phase III multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of canakinumab as adjuvant therapy in adult subjects with stages II-IIIA and NSCLC following complete surgical resection. The primary endpoint is disease-free survival
Cemiplimab (Libtayo)- Regeneron Pharmaceuticals/Sanofi
Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. The open-label, randomized, multi-center Phase 3 trial investigated the first-line treatment of Libtayo monotherapy compared to platinum-doublet chemotherapy in squamous or non-squamous advanced NSCLC that tested positive for PD-L1 in 50% of tumor cells. A separate Phase 3 trial evaluating a first-line combination of Libtayo and chemotherapy in patients with advanced NSCLC irrespective of PD-L1 expression is also underway and expected to be fully enrolled in 2020.
Further product details are provided in the report..
Non-Small Cell Lung Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Non-Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Non-Small Cell Lung Cancer
There are approx. 200+ key companies which are developing the therapies for Non-Small Cell Lung Cancer. The companies which have their Non-Small Cell Lung Cancer drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Merck, Eisai, Novartis Pharmaceuticals, Ariad Pharmaceuticals, Takeda, Regeneron Pharmaceuticals, Innovent Biologics etc.
DelveInsights report covers around 200+ products under different phases of clinical development like
Mid-stage products (Phase II and Phase I/II)
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Non-Small Cell Lung Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non-Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Small Cell Lung Cancer drugs.
The companies and academics are working to assess challenges and seek opportunities that could influence Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Non-Small Cell Lung Cancer.
August 2020: Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusionpositive Non-Small Cell Lung Cancer who had previously received platinum-based chemotherapy and those who were previously untreated.
Non-Small Cell Lung Cancer Report Insights
Non-Small Cell Lung Cancer Pipeline Analysis
Impact of Drugs
Non-Small Cell Lung Cancer Report Assessment
Pipeline Product Profiles
Inactive drugs assessment
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Non-Small Cell Lung Cancer drugs?
How many Non-Small Cell Lung Cancer drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Small Cell Lung Cancer?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Non-Small Cell Lung Cancer therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Non-Small Cell Lung Cancer and their status?
What are the key designations that have been granted to the emerging drugs?
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Millennium Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc.
Bristol Myers Squibb
Daiichi Sankyo, Inc.
Hanmi Pharmaceutical Company Limited
TYK Medicines, Inc
Have query on this report?Make an Enquiry
Non-Small Cell Lung Cancer: Overview
Mechanism of Action
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Oncology
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017